<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772616</url>
  </required_header>
  <id_info>
    <org_study_id>2007/13</org_study_id>
    <nct_id>NCT00772616</nct_id>
  </id_info>
  <brief_title>Influence of Intraoperative Analgesia on the Postoperative Morphine Consumption</brief_title>
  <official_title>Influence of Intraoperative Analgesia (Sufentanil Administered According to the Usual Criteria or Remifentanil Administered by a Closed-loop System Using Bispectral Index as the Controller) on the Postoperative Morphine Consumption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unlike longer acting opiates (sufentanil), remifentanil may provoke postoperative
      hyperalgesia. We have developed two automated bispectral index - guided drug delivery
      systems: one for propofol administration, the other for combined propofol and remifentanil
      administration. Both systems achieve the same objective: similar level of anesthesia
      indicated by bispectral index levels between 40 to 60. We make the assumption that this
      method of automated remifentanil administration may avoid postoperative hyperalgesia.
      Patients scheduled for abdominal surgery will be divided into two groups:

        -  in one group, patients will receive automatically delivered propofol and manually
           delivered sufentanil according to the usual criteria,

        -  in the other group, patients will receive propofol and remifentanil both automatically
           administered.

      Assessment of postoperative hyperalgesia will be primarily based on morphine consumption
      (patient controlled analgesia) and detection of cutaneous hyperalgesia areas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of morphine administered during the postoperative period (patient controlled analgesia)</measure>
    <time_frame>48 postoperative hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain scores</measure>
    <time_frame>48 postoperative hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative hyperalgesia</measure>
    <time_frame>up to 5th to 7th postoperative days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea vomiting</measure>
    <time_frame>48 postoperative hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>closed-loop administration using bispectral index as the single input for the controller.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>dosage according to usual criteria</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients scheduled for an abdominal surgery

        Exclusion Criteria:

          -  Age less than 18 years,

          -  Pregnant women,

          -  Allergy to propofol, sufentanil, remifentanil, morphine, muscle relaxant, or to a
             component,

          -  Hypersensibility to sufentanil, remifentanil or to a derivate of fentanyl,

          -  Inflammatory bowel disease,

          -  Chronic pain,

          -  Patients receiving a psychotropic treatment or a a morphine agonist-antagonist,

          -  Alcoholic patients and patients taking opiates,

          -  History of neurological disorders or central brain lesion, of severe respiratory
             insufficiency, of hepatic insufficiency,

          -  Emergency surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Fischler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, Sessler DI, Chauvin M. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005 Jul;103(1):147-55.</citation>
    <PMID>15983467</PMID>
  </reference>
  <reference>
    <citation>Liu N, Chazot T, Genty A, Landais A, Restoux A, McGee K, LaloÃ« PA, Trillat B, Barvais L, Fischler M. Titration of propofol for anesthetic induction and maintenance guided by the bispectral index: closed-loop versus manual control: a prospective, randomized, multicenter study. Anesthesiology. 2006 Apr;104(4):686-95.</citation>
    <PMID>16571963</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2008</study_first_submitted>
  <study_first_submitted_qc>October 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Patient-Controlled Analgesia</keyword>
  <keyword>Hyperalgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

